Human Genome submits ABthrax BLA

Human Genome Sciences Inc. (NASDAQ:HGSI) submitted a BLA to FDA for ABthrax raxibacumab to treat inhalation anthrax. ABthrax is a human mAb against Bacillus anthracis protective antigen that is being...